Psychiatr. praxi. 2023;24(3):140-147 | DOI: 10.36290/psy.2023.027

New trends in schizophrenia treatment

MUDr. Miloslav Kopeček, Ph.D.1, 2, prof. MUDr. Jiří Masopust, Ph.D.3, doc. MUDr. Martin Anders, Ph.D.4
1 Národní ústav duševního zdraví, Klecany
2 Psychiatrická a psychologická klinika 3. LF UK, Praha
3 Psychiatrická klinika LF UK a FN, Hradec Králové ⁴Psychiatrická klinika 1. LF UK a VFN, Praha

Antipsychotics are the mainstay of schizophrenia treatment. Psychopharmac, repetitive transcranial magnetic stimulation (rTMS) or electroconvulsive therapy (ECT) form a biological component that is supplemented at all levels of treatment with psychosocial interventions within the bio-psycho-social approach in the treatment of schizophrenia. The goal of schizophrenia treatment is not only the reduction of positive symptoms, as was the case in the past, but the achievement of functional remission. The treatment of schizophrenia can be thought of as a step-by-step climbing of stairs, where each level of the staircase represents a specific treatment goal. The treatment of schizophrenia with one antipsychotic is rather an exception. More often, it is a sequence of therapeutic interventions that respond to the effect but also tolerability of the treatment.

Keywords: schizophrenia, treatment, review, side efect.

Accepted: October 9, 2023; Published: October 16, 2023  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kopeček M, Masopust J, Anders M. New trends in schizophrenia treatment. Psychiatr. praxi. 2023;24(3):140-147. doi: 10.36290/psy.2023.027.
Download citation

References

  1. Ustohal L, Kašpárek T. Léčba akutní epizody schizofrenie - aktualizace doporučených postupů. Psychiatr. 2023;27(1):35-39.
  2. Masopust J, Kopeček M, Protopopová D. Stabilizační a udržovací léčba schizofrenie. Available from: Doporučené postupy psychiatrické péče Psychiatrické společnosti ČLS JEP. 2022 https://postupy-pece.psychiatrie.cz/specialni-psychiatrie/f2-schizofrenie/lecba-akutni-epizody-schizofrenie.
  3. Bak M, Weltens I, Bervoets C, et al. The pharmacological management of agitated and aggressive behaviour: A systematic review and meta-analysis. Eur Psychiatry. 2019;57:78-100. Go to original source... Go to PubMed...
  4. Vevera J. Diazepam i.m. - nejčastěji užívaný, ale nevhodný lék ke zvládání akutní úzkosti, agitovanosti a agresivity. Cesk Slov Neurol. 2014;N 77/110 (6):760-764. Go to original source...
  5. Kališová L, Kitzlerová E, Petr T. Používání omezovacích prostředků. In Psychiatrická společnost ČLS JEP: Doporučené postupy psychiatrické péče 2021. Available from: https://postupy-pece.psychiatrie.cz/lecba/omezovaci-prostredky/pouzivani-omezovacich-prostredku.
  6. Huhn M, Nikolakopoulou A, Schneider-Thoma J, et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet. 2019;394(10202):939-951. Go to original source... Go to PubMed...
  7. Sherwood M, Thornton AE, Honer WG. A meta-analysis of profile and time-course of symptom change in acute schizophrenia treated with atypical antipsychotics. Int J Neuropsychopharmacol. 2006;9(3):357-66. Go to original source... Go to PubMed...
  8. Češková E, Šilhán P, Kacířová I, et al. Terapeutické monitorování léčiv v psychiatrii. Available from: Doporučené postupy psychiatrické péče Psychiatrické společnosti ČLS JEP. 2018. https://postupy-pece.psychiatrie.cz/lecba/monitorovani-lecby-psychofarmaky/terapeuticke-monitorovani-leciv-v-psychiatrii.
  9. Kahn RS, Winter van Rossum I, Leucht S, et al. Amisulpride and olanzapine followed by open-label treatment with clozapine in first-episode schizophrenia and schizophreniform disorder (OPTiMiSE): a three-phase switching study. Lancet Psychiatry. 2018;5(10):797-807. Go to original source... Go to PubMed...
  10. Kane J, Honigfeld G, Singer J, et al. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry. 1988;45(9):789-96. Go to original source... Go to PubMed...
  11. Klírová M., Novák T, Buday J. 2023 Repetitivní transkraniální magnetická stimulace (rTMS). Available from: In Doporučené postupy psychiatrické péče Psychiatrické společnosti ČLS JEP. 2023. https://postupy-pece.psychiatrie.cz/lecba/biologicke-metody/rtms.
  12. Buday J, Klírová M, Novák T. 2023 Elektrokonvulzivní terapie (EKT). Available from: Doporučené postupy psychiatrické péče Psychiatrické společnosti ČLS JEP. 2023. https://postupy-pece.psychiatrie.cz/lecba/biologicke-metody/ekt
  13. Taylor DM, Barnes TRE, Young AH. The Maudsley prescribing guidelines in psychiatry. 14th ed. West Sussex, United Kingdom: John Wiley & Sons. 2021;956. Go to original source...
  14. Andreasen NC, Carpenter WT Jr, Kane JM, et al. Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry. 2005;162(3):441-9. Go to original source... Go to PubMed...
  15. Baldez DP, Biazus TB, Rabelo-da-Ponte FD, et al. The effect of antipsychotics on the cognitive performance of individuals with psychotic disorders: Network meta-analyses of randomized controlled trials. Neurosci Biobehav Rev. 2021;126:265-275. Go to original source... Go to PubMed...
  16. Krynicki CR, Upthegrove R, Deakin JFW, et al. The relationship between negative symptoms and depression in schizophrenia: a systematic review. Acta Psychiatr Scand. 2018;137(5):380-390. Go to original source... Go to PubMed...
  17. Libiger J. Negativní symptomy: odolné jádro schizofrenie. Psychiatrie 2018;22(1):39-47.
  18. Masopust J, Mohr P, Kopeček M. Antipsychotika v léčbě predominantních negativních příznaků schizofrenie: aktualizace doporučených postupů. Psychiatrie. 2020;24 (1):40-43.
  19. Achtyes ED, Hopkins SC, Dedic N, et al. Ulotaront: review of preliminary evidence for the efficacy and safety of a TAAR1 agonist in schizophrenia. Eur Arch Psychiatry Clin Neurosci. 2023;273(7):1543-1556. Go to original source... Go to PubMed...
  20. Mitchell AJ, Lord O, Malone D.Differences in the prescribing of medication for physical disorders in individuals with v. without mental illness: meta-analysis. Br J Psychiatry. 2012;201:435-443. Go to original source... Go to PubMed...
  21. Correll CU, Detraux J, De Lepeleire J, et al. Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder. World Psychiatry. 2015;14:119-136. Go to original source... Go to PubMed...
  22. Achtyes E, Simmons A, Skabeev A, et al. Patient preferences concerning the efficacy and side-effect profile of schizophrenia medications: a survey of patients living with schizophrenia. BMC Psychiatry. 2018;18(1):292. Go to original source... Go to PubMed...
  23. Kearns B, Cooper K, Cantrell A, et al. Schizophrenia Treatment with Second-Generation Antipsychotics: A Multi-Country Comparison of the Costs of Cardiovascular and Metabolic Adverse Events and Weight Gain. Neuropsychiatr Dis Treat. 2021;17:125-137. Go to original source... Go to PubMed...
  24. Masopust J, Kopeček M, Blaha V. Sledování tělesného zdraví u pacientů závažnými neorganickými duševními poruchami (psychózy, bipolární porucha, depresivní porucha). Available from: Doporučené postupy psychiatrické péče Psychiatrické společnosti ČLS JEP. 2023. https://postupy-pece.psychiatrie.cz/obecna-psychiatrie/sledovani-telesneho-zdravi.
  25. Visseren FLJ, Mach F, Smulders YM, et al. ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42(34):3227-3337. Go to original source... Go to PubMed...
  26. Vrablík M, Cífková R, Tuka V, et al. Doporučený postup Evropské kardiologické společnosti pro prevenci kardiovaskulárních onemocnění v klinické praxi 2021.Souhrn dokumentu připravený Českou kardiologickou společností. Cor Vasa. 2022;64(2):165-211. Go to original source...
  27. Abosi O, Lopes S, Schmitz S, et al. Cardiometabolic effects of psychotropic medications. Horm Mol Biol Clin Investigů. 2018; 36(1):/j/hmbci.2018.36.issue-1/hmbci-2017-0065/hmbci-2017-0065.xml. Go to original source... Go to PubMed...
  28. Pillinger T, McCutcheon RA, Vano L, et al. Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis. Lancet Psychiatry. 2020;7:64-77. Go to original source... Go to PubMed...
  29. Kolenic M, Franke K, Hlinka J, et al. Obesity, dyslipidemia and brain age in first-episode psychosis. J Psychiatr Res 2018;99:151-158. Go to original source... Go to PubMed...
  30. McWhinney S, Kolenic M, Franke K, et al. Obesity as a Risk Factor for Accelerated Brain Ageing in First-Episode Psychosis-A Longitudinal Study. Schizophr Bull. 2021;47(6):1772-1781. Go to original source... Go to PubMed...
  31. Vochoskova K, McWhinney SR, Fialova M, et al. Weight and metabolic changes in early psychosis-association with daily quantification of medication exposure during the first hospitalization. Acta Psychiatr Scand. 2023;148(3):265-276. Go to original source... Go to PubMed...




Psychiatry for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.